Bay Area's PaxVax, Inc. Pockets $14 Million
BioVentrix raised $14 million in a new round of equity funding and said it performed the 1st implantation of its micro-anchor Revivent device in a pre-clinical model.
The Revivent treatment is a transcatheter-based procedure known as less invasive ventricular enhancement that reduces the overall size of the wall of the heart’s left ventricle, without the need for cardiopulmonary bypass or incisions in the heart, according to the company.
The funds came from 64 anonymous investors, with the company looking to pull in another $3.5 million before the round closes, according to an SEC filing.
The Revivent treatment is a transcatheter-based procedure known as less invasive ventricular enhancement that reduces the overall size of the wall of the heart’s left ventricle, without the need for cardiopulmonary bypass or incisions in the heart, according to the company.
The funds came from 64 anonymous investors, with the company looking to pull in another $3.5 million before the round closes, according to an SEC filing.